Targeting telomerase-expressing cancer cells

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 7, 2011, Pages 1433-1442

  Ouellette, Michel M ^a   Wright, Woodring E ^b   Shay, Jerry W ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer therapy; Immortality; Senescence; Telomerase; Telomeres

Indexed keywords

ONCOLYTIC VIRUS; TELOMERASE;

CELL AGING; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MITOSIS; NEOPLASM; PHYSIOLOGY; REVIEW; TELOMERE;

CELL AGING; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; MITOSIS; NEOPLASMS; ONCOLYTIC VIRUSES; TELOMERASE; TELOMERE;

EID: 79959440167     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01279.x     Document Type: Review

References (90)

1. Harley CB. Telomere loss: mitotic clock or genetic time bomb Mutat Res. 1991; 256: 271-82.
2. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol. 1996; 8: 66-71.
3. Kim NW, Piatyszek MA, Prowse KR, et al Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266: 2011-5.
4. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33: 787-91.
5. Hahn WC, Stewart SA, Brooks MW, et al Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999; 5: 1164-70.
6. Zhang X, Mar V, Zhou W, et al Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999; 13: 2388-99.
7. de Lange T. Protection of mammalian telomeres. Oncogene. 2002; 21: 532-40.
8. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005; 19: 2100-10.
9. Liu D, O'Connor MS, Qin J, et al Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins. J Biol Chem. 2004; 279: 51338-42.
10. de Lange T. T-loops and the origin of telomeres. Nat Rev Mol Cell Biol. 2004; 5: 323-9.
11. Karlseder J, Broccoli D, Dai Y, et al p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 1999; 283: 1321-5.
12. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003; 13: 1549-56.
13. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol. 1972; 239: 197-201.
14. Wu P, van Overbeek M, Rooney S, et al Apollo contributes to G overhang maintenance and protects leading-end telomeres. Mol Cell. 2010; 39: 606-17.
15. Lam YC, Akhter S, Gu P, et al SNMIB/Apollo protects leading-strand telomeres against NHEJ-mediated repair. EMBO J. 2010; 29: 2230-41.
16. Ouellette MM, Choi KH. Telomeres and telomerase in ageing and cancer. Encyclopedia of life sciences (). Chichester, UK: John Wiley & Sons Ltd; 2007.
17. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res. 1991; 196: 33-9.
18. Robles SJ, Adami GR. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 1998; 16: 1113-23.
19. Smogorzewska A, Karlseder J, Holtgreve-Grez H, et al DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol. 2002; 12: 1635-44.
20. Macera-Bloch L, Houghton J, Lenahan M, et al Termination of lifespan of SV40-transformed human fibroblasts in crisis is due to apoptosis. J Cell Physiol. 2002; 190: 332-44.
21. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene. 2002; 21: 564-79.
22. Feng J, Funk WD, Wang SS, et al The RNA component of human telomerase. Science. 1995; 269: 1236-41.
23. Harrington L, Zhou W, McPhail T, et al Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 1997; 11: 3109-15.
24. Meyerson M, Counter CM, Eaton EN, et al hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997; 90: 785-95.
25. Nakamura TM, Morin GB, Chapman KB, et al Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997; 277: 955-9.
26. Herbert BS, Hochreiter AE, Wright WE, et al Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat Protoc. 2006; 1: 1583-90.
27. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 1995; 23: 3794-5.
28. Hess JL, Highsmith WE Jr. Telomerase detection in body fluids. Clin Chem. 2002; 48: 18-24.
29. Wright WE, Piatyszek MA, Rainey WE, et al Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996; 18: 173-9.
30. Ulaner GA, Giudice LC. Developmental regulation of telomerase activity in human fetal tissues during gestation. Mol Hum Reprod. 1997; 3: 769-73.
31. Forsyth NR, Wright WE, Shay JW. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation. 2002; 69: 188-97.
32. Hahn WC, Counter CM, Lundberg AS, et al Creation of human tumour cells with defined genetic elements. Nature. 1999; 400: 464-8.
33. Henson JD, Neumann AA, Yeager TR, et al Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002; 21: 598-610.
34. Hiyama E, Hiyama K, Yokoyama T, et al Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med. 1995; 1: 249-55.
35. Ouellette MM, Lee K. Telomerase: diagnostics, cancer therapeutics and tissue engineering. Drug Discov Today. 2001; 6: 1231-7.
36. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol. 1992; 27: 383-9.
37. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002; 2: 257-65.
38. Shay JW, Wright WE. Mechanism-based combination telomerase inhibition therapy. Cancer Cell. 2005; 7: 1-2.
39. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol. 2001; 19: 114-20.
40. Hamilton SE, Pitts AE, Katipally RR, et al Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry. 1997; 36: 11873-80.
41. Norton JC, Piatyszek MA, Wright WE, et al Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol. 1996; 14: 615-9.
42. Herbert BS, Pongracz K, Shay JW, et al Oligonucleotide N3'->P5' phosphoramidates as efficient telomerase inhibitors. Oncogene. 2002; 21: 638-42.
43. Asai A, Oshima Y, Yamamoto Y, et al A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003; 63: 3931-9.
44. Gryaznov S, Pongracz K, Matray T, et al Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids. 2001; 20: 401-10.
45. Dikmen ZG, Gellert GC, Jackson S, et al In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005; 65: 7866-73.
46. Gellert GC, Dikmen ZG, Wright WE, et al Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat. 2006; 96: 73-81.
47. Chen Z, Koeneman KS, Corey DR. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res. 2003; 63: 5917-25.
48. Djojosubroto MW, Chin AC, Go N, et al Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology. 2005; 42: 1127-36.
49. Herbert BS, Gellert GC, Hochreiter AE, et al Lipid modification of GRN163, an N3'->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005; 24: 5262-8.
50. Perry PJ, Arnold JR, Jenkins TC. Telomerase inhibitors for the treatment of cancer: the current perspective. Expert Opin Investig Drugs. 2001; 10: 2141-56.
51. Shammas MA, Qazi A, Batchu RB, et al Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008; 14: 4971-80.
52. Dikmen ZG, Wright WE, Shay JW, et al Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells. J Cell Biochem. 2008; 104: 444-52.
53. Shammas MA, Koley H, Bertheau RC, et al Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 2008; 22: 1410-8.
54. Hochreiter AE, Xiao H, Goldblatt EM, et al Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res. 2006; 12: 3184-92.
55. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol. 2008; 1: 20-8.
56. Clarke MF, Dick JE, Dirks PB, et al Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66: 9339-44.
57. Allan AL, Vantyghem SA, Tuck AB, et al Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2006; 26: 87-98.
58. Farnie G, Clarke RB. Breast stem cells and cancer. Ernst Schering Found Symp Proc. 2006; 5: 141-53.
59. Hermann PC, Huber SL, Herrler T, et al Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1: 313-23.
60. Li C, Heidt DG, Dalerba P, et al Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 1030-7.
61. Brennan SK, Wang Q, Tressler R, et al Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One. 2010; 5: e12487.
62. Joseph I, Tressler R, Bassett E, et al The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010; 70: 9494-504.
63. Marian CO, Cho SK, McEllin BM, et al The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res. 2010; 16: 154-63.
64. Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer. 2010; 127: 321-31.
65. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997; 9: 684-93.
66. Vonderheide RH, Hahn WC, Schultze JL, et al The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999; 10: 673-9.
67. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002; 21: 674-9.
68. Bernhardt SL, Gjertsen MK, Trachsel S, et al Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer. 2006; 95: 1474-82.
69. Brunsvig PF, Aamdal S, Gjertsen MK, et al Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2006; 55: 1553-64.
70. Greten TF, Forner A, Korangy F, et al A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010; 10: 209-13.
71. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008; 8: 167-9.
72. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs. 2009; 18: 687-94.
73. Katz MH, Spivack DE, Takimoto S, et al Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol. 2003; 10: 762-72.
74. Liu J, Zou WG, Lang MF, et al Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int J Oncol. 2002; 21: 661-6.
75. Majumdar AS, Hughes DE, Lichtsteiner SP, et al The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 2001; 8: 568-78.
76. Plumb JA, Bilsland A, Kakani R, et al Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene. 2001; 20: 7797-803.
77. Schepelmann S, Ogilvie LM, Hedley D, et al Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res. 2007; 67: 4949-55.
78. Zhou JH, Tang B, Liu XL, et al hTERT-targeted E. coli purine nucleoside phosphorylase gene/6-methylpurine deoxyribose therapy for pancreatic cancer. Chin Med J. 2007; 120: 1348-52.
79. Kyo S, Takakura M, Fujiwara T, et al Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008; 99: 1528-38.
80. Irving J, Wang Z, Powell S, et al Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 2004; 11: 174-85.
81. Kawashima T, Kagawa S, Kobayashi N, et al Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004; 10: 285-92.
82. Lanson NA Jr, Friedlander PL, Schwarzenberger P, et al Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 2003; 63: 7936-41.
83. Wirth T, Zender L, Schulte B, et al A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003; 63: 3181-8.
84. Nemunaitis J, Tong AW, Nemunaitis M, et al A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 2010; 18: 429-34.
85. Liao Z, Huang C, Zhou F, et al Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. Cancer Lett. 2009; 283: 20-8.
86. Zhang JF, Wei F, Wang HP, et al Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res. 2010; 29: 52-7.
87. Shay JW. Telomerase in human development and cancer. J Cell Physiol. 1997; 173: 266-70.
88. Langford LA, Piatyszek MA, Xu RS, et al Telomerase activity in ordinary meningiomas predicts poor outcome. Human Pathol. 1997; 28: 416-20.
89. Wright WE, Shay JW. Time, telomeres and tumors. Is cellular senescence more than an anticancer mechanism Trends Cell Biol. 1995; 5: 293-7.
90. Shay JW. Aging and Cancer - are telomeres and telomerase the connection Mol Med Today. 1995; 1: 378-84.